Plasma Biomarkers for Colorectal, Lung, and Ovarian Cancer Detection

937 plasma samples from the Uppsala-Umeå cancer biobank (U-CAN) include measurements of 165 proteins and 244 metabolites. The dataset covers 330 colorectal cancer, 304 lung cancer, 184 ovarian cancer cases, and 119 non-cancer controls. Protein levels were measured via ELISA at Uppsala University, and metabolite levels via NMR spectroscopy at Nightingale Health.

Use Cases

• Developing biomarker panels for colorectal cancer detection based on plasma protein and metabolite levels.
• Building classification models for lung cancer detection based on combined proteomic and metabolomic features.
• Identifying potential biomarkers for ovarian cancer using multi-omic plasma data.
• Comparing proteomic and metabolomic signatures across different cancer types and non-cancer controls.

Strengths

• 937 individual samples provide a substantial cohort for analysis.
• Includes measurements for 165 plasma proteins and 244 metabolites, offering multi-modal data.
• Clear breakdown of sample types: 330 colorectal cancer, 304 lung cancer, 184 ovarian cancer, and 119 controls.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• Data may reflect geographic bias inherent to the Uppsala-Umeå cancer biobank.

Provenance

Source

Uppsala-Umeå cancer biobank (U-CAN)

Collection Method

Protein levels acquired by ELISA (BioPlex 200), metabolite levels acquired by NMR spectroscopy.

Freshness

Last updated 2026-04-10 09:28:49; freshness should be verified.

Geography

Likely Sweden (Uppsala-Umeå biobank) and Finland (Nightingale Health, Helsinki).